Ventyx Biosciences (Ventyx Biosciences) Cash-to-Debt : 20.17 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Ventyx Biosciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Ventyx Biosciences's cash to debt ratio for the quarter that ended in Dec. 2023 was 20.17.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Ventyx Biosciences could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Ventyx Biosciences's Cash-to-Debt or its related term are showing as below:

VTYX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02 Med: 20.17 Max: No Debt
Current: 20.17

During the past 5 years, Ventyx Biosciences's highest Cash to Debt Ratio was No Debt. The lowest was 0.02. And the median was 20.17.

VTYX's Cash-to-Debt is ranked better than
64.85% of 1539 companies
in the Biotechnology industry
Industry Median: 6.5 vs VTYX: 20.17

Ventyx Biosciences Cash-to-Debt Historical Data

The historical data trend for Ventyx Biosciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Ventyx Biosciences Cash-to-Debt Chart

Ventyx Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

0.08

0.02

No Debt

204.07

20.17

Ventyx Biosciences Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial											204.07	257.81	244.12	24.39	20.17

Competitive Comparison of Ventyx Biosciences's Cash-to-Debt

For the Biotechnology subindustry, Ventyx Biosciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ventyx Biosciences's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ventyx Biosciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Ventyx Biosciences's Cash-to-Debt falls into.

Ventyx Biosciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Ventyx Biosciences's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	252.22	/	(1.001	+	11.505)
	=	20.17

Ventyx Biosciences's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	252.22	/	(1.001	+	11.505)
	=	20.17

Ventyx Biosciences (NAS:VTYX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Ventyx Biosciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Ventyx Biosciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Ventyx Biosciences (Ventyx Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ventyx Biosciences Inc (NAS:VTYX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

662 Encinitas Boulevard, Suite 250, Encinitas, CA, USA, 92024

Website

https://www.ventyxbio.com

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its lead product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

Executives

Raju Mohan	director, officer: Chief Executive Officer	C/O VENTYX BIOSCINECES, INC., 332 ENCINITAS BLVD., SUITE 200, ENCINITAS CA 92024
John Nuss	officer: Chief Scientific Officer	C/O VENTYX BIOSCIENCES, INC., 332 ENCINITAS BLVD. SUITE 200, ENCINITAS CA 92024
Christopher W Krueger	officer: Chief Business Officer	C/O ARDEA BIOSCIENCES INC, 2131 PALOMAR AIRPORT ROAD SUITE 300, CARLSBAD CA 92011
Nsv Partners Iii Lp	10 percent owner	500 WEST PUTNAM AVE, SUITE 400, GREENWICH CT 06830
Somu Subramaniam	director, 10 percent owner	C/O ICAD INC, 98 SPIT BROOK ROAD SUITE 100, NASHUA NH 03062
Martin Auster	officer: Chief Financial Officer	C/O VENTYX BIOSCIENCES, INC., 662 ENCINITAS BLVD. STE 250, ENCINITAS CA 92024
William J. Sandborn	officer: See Remarks	C/O VENTYX BIOSCIENCES, INC., 662 ENCINITAS BLVD. STE 250, ENCINITAS CA 92024
Sheila Gujrathi	director	10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
William Richard White	director	C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Onaiza Cadoret-manier	director	2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
Allison Hulme	director	C/O SOPHIRIS BIO INC., 1258 PROSPECT ST, LA JOLLA CA 92037
Venbio Global Strategic Fund Iii, L.p.	10 percent owner, other: See Remarks	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Aaron Royston	director, 10 percent owner	200 CARDINAL WAY, 2ND FLOOR, REDWOOD CITY CA 94063
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iii Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116